BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

ENZYVANT THERAPEUTICS GMBH — Lobbying — Receipts Report

LD-2 disclosure · 1st Quarter - Report

ENZYVANT THERAPEUTICS GMBH

via JEFFREY J. KIMBELL & ASSOCIATES, INC.

1st Quarter (Jan 1 - Mar 31) · 2021Posted Apr 21, 2021Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: ENZYVANT THERAPEUTICS GMBH
Description: Biopharmaceutical company
Location: Massachusetts · United States of America

Registrant

Firm: JEFFREY J. KIMBELL & ASSOCIATES, INC.
Description: Consulting Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
education about rare disease therapies
Lobbyistsmr JEFFREY J KIMBELL · JODIE LOCKHART · JOHN HERZOG · KEITH STUDDARD · JOHN R RAY · DAVID RUDLOFF · mr KENNETH LEE HODGE
Covered position (JOHN HERZOG): Health Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the President
Covered position (KEITH STUDDARD): Legislative Director, Rep. Marsha Blackburn
Covered position (JOHN R RAY): Legislative Assistant, Rep. Mike Kelly
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.